RU2011108579A - Антитело против удлиненного гликосфинголипида i типа, его производные и применение - Google Patents
Антитело против удлиненного гликосфинголипида i типа, его производные и применение Download PDFInfo
- Publication number
- RU2011108579A RU2011108579A RU2011108579/10A RU2011108579A RU2011108579A RU 2011108579 A RU2011108579 A RU 2011108579A RU 2011108579/10 A RU2011108579/10 A RU 2011108579/10A RU 2011108579 A RU2011108579 A RU 2011108579A RU 2011108579 A RU2011108579 A RU 2011108579A
- Authority
- RU
- Russia
- Prior art keywords
- antibody according
- antibody
- chain
- variable region
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
1. Человеческое моноклональное антитело или его антигенсвязывающая часть, которое специфично связывает эпитоп, содержащий удлиненную цепь I типа, содержащую Leb, где указанный эпитоп экспрессируется в клетках злокачественных новообразований, и где указанное антитело или его антигенсвязывающая часть не связываются с Ley. ! 2. Антитело по п.1, которое не связывается Lex. ! 3. Антитело п.1, которое не связывается Ley-Lex. ! 4. Антитело по п.1, которое лизирует около 50% клеток Colo205 в ADCC-анализе, проводимом при соотношении Э/М (эффекторные клетки/клетки-мишени) около 20/1 и при концентрации антитела около 5 пг/мл. ! 5. Антитело по п.1, где указанная клетка злокачественного новообразования экспрессирует Leb-Lea. ! 6. Антитело по п.1, где указанная клетка злокачественного новообразования является эпителиальной клеткой. ! 7. Антитело по п.6, где указанная эпителиальная клетка включает клетки толстой кишки, прямой кишки, пищевода, легкого, простаты, молочной железы или поджелудочной железы. ! 8. Антитело по п.1, которое представляет собой scFv. ! 9. Антитело по п.1, которое содержит κ-цепь. ! 10. Антитело по п.1, которое содержит γ-цепь. ! 11. Антитело по п.1, которое содержит гипервариабельные области (CDR), полученные из GNX-8. ! 12. Антитело по п.1, которое содержит вариабельную область тяжелой цепи, имеющую аминокислотную последовательность SEQ ID NO: 15. ! 13. Антитело по п.12, в котором вариабельная область тяжелой цепи кодируется нуклеотидной последовательностью SEQ ID NO: 14. ! 14. Антитело по п.12, которое дополнительно содержит вариабельную область легкой цепи, имеющую аминокислотную последовательность SEQ ID NO: 17. ! 15. Антитело по п.14, в котором вариабельная область легкой цепи к
Claims (18)
1. Человеческое моноклональное антитело или его антигенсвязывающая часть, которое специфично связывает эпитоп, содержащий удлиненную цепь I типа, содержащую Leb, где указанный эпитоп экспрессируется в клетках злокачественных новообразований, и где указанное антитело или его антигенсвязывающая часть не связываются с Ley.
2. Антитело по п.1, которое не связывается Lex.
3. Антитело п.1, которое не связывается Ley-Lex.
4. Антитело по п.1, которое лизирует около 50% клеток Colo205 в ADCC-анализе, проводимом при соотношении Э/М (эффекторные клетки/клетки-мишени) около 20/1 и при концентрации антитела около 5 пг/мл.
5. Антитело по п.1, где указанная клетка злокачественного новообразования экспрессирует Leb-Lea.
6. Антитело по п.1, где указанная клетка злокачественного новообразования является эпителиальной клеткой.
7. Антитело по п.6, где указанная эпителиальная клетка включает клетки толстой кишки, прямой кишки, пищевода, легкого, простаты, молочной железы или поджелудочной железы.
8. Антитело по п.1, которое представляет собой scFv.
9. Антитело по п.1, которое содержит κ-цепь.
10. Антитело по п.1, которое содержит γ-цепь.
11. Антитело по п.1, которое содержит гипервариабельные области (CDR), полученные из GNX-8.
12. Антитело по п.1, которое содержит вариабельную область тяжелой цепи, имеющую аминокислотную последовательность SEQ ID NO: 15.
13. Антитело по п.12, в котором вариабельная область тяжелой цепи кодируется нуклеотидной последовательностью SEQ ID NO: 14.
14. Антитело по п.12, которое дополнительно содержит вариабельную область легкой цепи, имеющую аминокислотную последовательность SEQ ID NO: 17.
15. Антитело по п.14, в котором вариабельная область легкой цепи кодируется нуклеотидной последовательностью SEQ ID NO: 16.
16. Композиция, содержащая антитело по п.1 и фармакологически активный агент.
17. Изделие, содержащее антитело по п.1 и детектируемую группировку.
18. Композиция, содержащая антитело по п.1 и фармацевтически приемлемый носитель, наполнитель или растворитель.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/075533 WO2010027364A1 (en) | 2008-09-07 | 2008-09-07 | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013105004/10A Division RU2013105004A (ru) | 2013-02-06 | 2013-02-06 | Антитело против удлиненного гликосфинголипида i типа, его производные и применение |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011108579A true RU2011108579A (ru) | 2012-09-10 |
| RU2478648C2 RU2478648C2 (ru) | 2013-04-10 |
Family
ID=41797355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011108579/10A RU2478648C2 (ru) | 2008-09-07 | 2008-09-07 | Антитело против удлиненного гликосфинголипида i типа, его производные и применение |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8163497B2 (ru) |
| EP (1) | EP2324060B1 (ru) |
| JP (1) | JP5611210B2 (ru) |
| KR (2) | KR101432474B1 (ru) |
| CN (1) | CN102282172B (ru) |
| AU (1) | AU2008361352B2 (ru) |
| BR (1) | BRPI0823049A2 (ru) |
| CA (1) | CA2735433C (ru) |
| DK (1) | DK2324060T3 (ru) |
| ES (1) | ES2549877T3 (ru) |
| HK (1) | HK1157363A1 (ru) |
| IL (1) | IL211561A (ru) |
| MX (1) | MX2011002478A (ru) |
| NZ (1) | NZ591488A (ru) |
| RU (1) | RU2478648C2 (ru) |
| TW (1) | TWI433684B (ru) |
| WO (1) | WO2010027364A1 (ru) |
| ZA (1) | ZA201101547B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703129B2 (en) * | 2008-09-07 | 2014-04-22 | GlycoNex, Inc. | Antibodies against extended type 1 chain antigens, derivatives thereof and use |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| GB201319374D0 (en) | 2013-11-01 | 2013-12-18 | Univ Nottingham | Glycans as functional cancer targets abd antibodies thereto |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| EP0232706A3 (en) * | 1986-01-10 | 1988-11-30 | Sloan-Kettering Institute For Cancer Research | Blood group antigen panel |
| US5168043A (en) | 1986-01-10 | 1992-12-01 | Sloan-Kettering Institute For Cancer Research | Blood group antigen panel |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5011920A (en) | 1986-01-30 | 1991-04-30 | Fred Hutchinson Cancer Research Center | Disialofucoganglioside immunogen and fucoganglioside monosialosyl Lea II |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| WO1989009825A1 (en) | 1988-04-16 | 1989-10-19 | Celltech Limited | Method for producing recombinant dna proteins |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5240833A (en) | 1989-01-30 | 1993-08-31 | The Biomembrane Institute | Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6432402B1 (en) * | 1989-05-25 | 2002-08-13 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| CA2018228C (en) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2095836C (en) | 1990-11-09 | 1999-04-06 | Stephen D. Gillies | Cytokine immunoconjugates |
| US6083929A (en) * | 1991-05-06 | 2000-07-04 | The Biomembrane Institute | Extended type 1 chain glycosphingolipids as tumor-associated antigens |
| ATE199647T1 (de) | 1991-05-14 | 2001-03-15 | Univ Connecticut | Gerichtete abgabe von genen, die immunogene proteine kodieren |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE195656T1 (de) | 1991-06-05 | 2000-09-15 | Univ Connecticut | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| HU218069B (hu) | 1992-06-09 | 2000-05-28 | Hoppe Ag. | Kilincses zárrendszer |
| EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE200625T1 (de) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | Leberreservezellen |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| WO2002002127A1 (en) * | 2000-07-03 | 2002-01-10 | Biomembrane Institute | Extended type 1 chain glycosphingolipids as tumor-associated antigens |
| US5795961A (en) | 1995-02-14 | 1998-08-18 | Ludwig Institute For Cancer Research | Recombinant human anti-Lewis b antibodies |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP2000508522A (ja) | 1996-03-22 | 2000-07-11 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | アポトーシス誘導分子ｉｉ |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
| KR20010031713A (ko) | 1997-11-03 | 2001-04-16 | 벤슨 로버트 에이치. | 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제 |
| CA2405557C (en) | 2000-04-12 | 2013-09-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| EP1916303B1 (en) * | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| JP3665316B2 (ja) * | 2001-05-18 | 2005-06-29 | 麒麟麦酒株式会社 | 抗ｔｒａｉｌ−ｒ抗体 |
| WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
-
2008
- 2008-09-07 EP EP08799283.0A patent/EP2324060B1/en active Active
- 2008-09-07 DK DK08799283.0T patent/DK2324060T3/en active
- 2008-09-07 MX MX2011002478A patent/MX2011002478A/es active IP Right Grant
- 2008-09-07 RU RU2011108579/10A patent/RU2478648C2/ru active
- 2008-09-07 BR BRPI0823049-8A patent/BRPI0823049A2/pt not_active IP Right Cessation
- 2008-09-07 WO PCT/US2008/075533 patent/WO2010027364A1/en active Application Filing
- 2008-09-07 US US12/299,013 patent/US8163497B2/en active Active
- 2008-09-07 CN CN200880131006.5A patent/CN102282172B/zh active Active
- 2008-09-07 NZ NZ591488A patent/NZ591488A/xx not_active IP Right Cessation
- 2008-09-07 KR KR1020147011352A patent/KR101432474B1/ko active IP Right Grant
- 2008-09-07 KR KR1020117007613A patent/KR101442323B1/ko active IP Right Grant
- 2008-09-07 JP JP2011526023A patent/JP5611210B2/ja active Active
- 2008-09-07 ES ES08799283.0T patent/ES2549877T3/es active Active
- 2008-09-07 AU AU2008361352A patent/AU2008361352B2/en active Active
- 2008-09-07 CA CA2735433A patent/CA2735433C/en active Active
-
2009
- 2009-08-06 TW TW098126571A patent/TWI433684B/zh active
-
2011
- 2011-02-28 ZA ZA2011/01547A patent/ZA201101547B/en unknown
- 2011-03-03 IL IL211561A patent/IL211561A/en active IP Right Grant
- 2011-10-31 HK HK11111704.1A patent/HK1157363A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010027364A1 (en) | 2010-03-11 |
| EP2324060A1 (en) | 2011-05-25 |
| MX2011002478A (es) | 2011-04-05 |
| KR20140066785A (ko) | 2014-06-02 |
| IL211561A0 (en) | 2011-05-31 |
| IL211561A (en) | 2016-04-21 |
| AU2008361352B2 (en) | 2013-05-09 |
| TW201010724A (en) | 2010-03-16 |
| EP2324060A4 (en) | 2011-10-19 |
| JP2012502027A (ja) | 2012-01-26 |
| KR20110076912A (ko) | 2011-07-06 |
| ZA201101547B (en) | 2012-05-30 |
| US8163497B2 (en) | 2012-04-24 |
| US20110142844A1 (en) | 2011-06-16 |
| ES2549877T3 (es) | 2015-11-02 |
| JP5611210B2 (ja) | 2014-10-22 |
| HK1157363A1 (zh) | 2012-06-29 |
| CN102282172A (zh) | 2011-12-14 |
| CA2735433C (en) | 2016-02-16 |
| TWI433684B (zh) | 2014-04-11 |
| DK2324060T3 (en) | 2015-10-26 |
| NZ591488A (en) | 2012-11-30 |
| KR101442323B1 (ko) | 2014-09-25 |
| CA2735433A1 (en) | 2010-03-11 |
| EP2324060B1 (en) | 2015-07-22 |
| KR101432474B1 (ko) | 2014-08-21 |
| BRPI0823049A2 (pt) | 2015-06-16 |
| RU2478648C2 (ru) | 2013-04-10 |
| CN102282172B (zh) | 2014-02-19 |
| AU2008361352A1 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264956B2 (en) | Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereof | |
| RU2019116661A (ru) | Антитела против pd-l1 и их варианты | |
| JP2020506971A5 (ru) | ||
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| JP2020524174A5 (ru) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2016116536A5 (ru) | ||
| JP2010535713A5 (ru) | ||
| JP2011505146A5 (ru) | ||
| JP2020534830A5 (ru) | ||
| JP2016536020A (ja) | 新規の抗クローディン抗体および使用方法 | |
| RU2008152332A (ru) | Антитела, распознающие содержащий углеводы эпитоп на cd43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения | |
| RU2010129423A (ru) | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках, и способы их применения | |
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| RU2010136940A (ru) | Антитела против альфа5-бета1 и их применение | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| JP2008532523A5 (ru) | ||
| JP2017518040A (ja) | 新規の抗ｒｎｆ４３抗体および使用方法 | |
| RU2013128444A (ru) | Новые модуляторы и способы их применения | |
| JP2020501598A5 (ru) | ||
| RU2012126098A (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |